Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study

dc.contributor.authorHeymer, Emma J.
dc.contributor.organizationfi=kliininen laitos|en=Department of Clinical Medicine|
dc.contributor.organization-code1.2.246.10.2458963.20.40612039509
dc.contributor.organization-code1.2.246.10.2458963.20.61334543354
dc.converis.publication-id386790060
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/386790060
dc.date.accessioned2025-08-28T03:08:54Z
dc.date.available2025-08-28T03:08:54Z
dc.description.abstract<p><strong>Background: </strong>Childhood cancer survivors are at risk of subsequent gliomas and meningiomas, but the risks beyond age 40 years are uncertain. We quantified these risks in the largest ever cohort.</p><p><strong>Methods: </strong>Using data from 69,460 5-year childhood cancer survivors (diagnosed 1940-2008), across Europe, standardized incidence ratios (SIRs) and cumulative incidence were calculated.</p><p><strong>Results: </strong>In total, 279 glioma and 761 meningioma were identified. CNS tumour (SIR: 16.2, 95% CI: 13.7, 19.2) and leukaemia (SIR: 11.2, 95% CI: 8.8, 14.2) survivors were at greatest risk of glioma. The SIR for CNS tumour survivors was still 4.3-fold after age 50 (95% CI: 1.9, 9.6), and for leukaemia survivors still 10.2-fold after age 40 (95% CI: 4.9, 21.4). Following cranial radiotherapy (CRT), the cumulative incidence of a glioma in CNS tumour survivors was 2.7%, 3.7% and 5.0% by ages 40, 50 and 60, respectively, whilst for leukaemia this was 1.2% and 1.7% by ages 40 and 50. The cumulative incidence of a meningioma after CRT in CNS tumour survivors doubled from 5.9% to 12.5% between ages 40 and 60, and in leukaemia survivors increased from 5.8% to 10.2% between ages 40 and 50.</p><p><strong>Discussion: </strong>Clinicians following up survivors should be aware that the substantial risks of meningioma and glioma following CRT are sustained beyond age 40 and be vigilant for symptoms.</p>
dc.format.pagerange986
dc.identifier.eissn1532-1827
dc.identifier.jour-issn0007-0920
dc.identifier.olddbid210270
dc.identifier.oldhandle10024/193297
dc.identifier.urihttps://www.utupub.fi/handle/11111/51101
dc.identifier.urlhttps://www.nature.com/articles/s41416-024-02577-y
dc.identifier.urnURN:NBN:fi-fe2025082792667
dc.language.isoen
dc.okm.affiliatedauthorLähteenmäki, Päivi
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3122 Cancersen_GB
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherSpringer Nature
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.doi10.1038/s41416-024-02577-y
dc.relation.ispartofjournalBritish Journal of Cancer
dc.relation.issue6
dc.relation.volume130
dc.source.identifierhttps://www.utupub.fi/handle/10024/193297
dc.titleRisk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study
dc.year.issued2024

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
s41416-024-02577-y.pdf
Size:
766.96 KB
Format:
Adobe Portable Document Format